首页> 外文期刊>Clinical Chemistry >High-Sensitivity Cardiac Troponin T for Early Prediction of Evolving Non-ST-Segment Elevation Myocardial Infarction in Patients with Suspected Acute Coronary Syndrome and Negative Troponin Results on Admission
【24h】

High-Sensitivity Cardiac Troponin T for Early Prediction of Evolving Non-ST-Segment Elevation Myocardial Infarction in Patients with Suspected Acute Coronary Syndrome and Negative Troponin Results on Admission

机译:高敏感性心肌肌钙蛋白T可早期预测可疑急性冠脉综合征患者发展中的非ST段抬高型心肌梗塞,且入院时肌钙蛋白阴性

获取原文
获取原文并翻译 | 示例
       

摘要

We sought to determine the diagnostic performance of the new high-sensitivity cardiac troponin T (hs-cTnT) assay for early detection of non-ST-segment myocardial infarction (NSTEMI) in patients with acute coronary syndrome. We enrolled patients with retrospectively confirmed unstable angina or NSTEMI and an initially negative cTnT concentration and compared the performance of baseline concentrations and serial changes in concentration within 3 and 6 h. Percentage change criteria included ≥20% δ change and ROC-optimized value. Based on the standard fourth-generation cTnT result of ≥0.03 µg/L, an evolving NSTEMI was diagnosed in 26 patients, and 31 patients were classified as having unstable angina. With the use of the hs-cTnT assay at the 99th-percentile cutoff, the percentage of NSTEMI cases detected increased gradually from 61.5% on presentation to 100% within 6 h, and the overall number of MI diagnoses increased by 34.6% (35 vs 26 cases). A δ change ≥20% or ≥ROC-optimized value of >117% within 3 h or ≥243% within 6 h yielded a specificity of 100% at sensitivities between 69% and 76%. The standard cTnT at the 99th percentile was less sensitive than hs-cTnT for early diagnosis of MI on presentation, and follow-up samples obtained within the initial 3 h demonstrated very low specificity of cTnT compared with hs-cTnT. The high-sensitivity cTnT assay increases the number of NSTEMI diagnoses and enables earlier detection of evolving NSTEMI. A doubling of the hs-cTnT concentration within 3 h in the presence of a second concentration ≥99th percentile is associated with a positive predictive value of 100% and a negative predictive value of 88%.
机译:我们试图确定新的高敏性心肌肌钙蛋白T(hs-cTnT)测定法对急性冠状动脉综合征患者的非ST段心肌梗死(NSTEMI)的早期检测的诊断性能。我们招募了回顾性证实不稳定型心绞痛或NSTEMI且最初cTnT浓度为负的患者,并比较了基线浓度和3到6小时内浓度的系列变化的表现。百分比变化标准包括≥20%δ变化和ROC优化值。根据标准的第四代cTnT结果≥0.03µg / L,在26例患者中诊断出正在发展的NSTEMI,并将31例患者分类为不稳定型心绞痛。在99%的临界值时使用hs-cTnT分析,发现的NSTEMI病例的百分比从呈现时的61.5%逐渐增加到6小时内的100%,并且MI诊断的总数增加了34.6%(35 vs 26例)。在3小时内δ变化≥20%或ROC优化值> 117%或在6小时内≥243%时,灵敏度在69%到76%之间产生100%的特异性。第99个百分位数的标准cTnT在出现MI时早期诊断中不如hs-cTnT敏感,并且与hs-cTnT相比,在最初3 h内获得的随访样品显示cTnT的特异性非常低。高灵敏度的cTnT分析可增加NSTEMI诊断的数量,并能及早发现正在发展的NSTEMI。在第二个浓度≥99%的情况下,在3小时内将hs-cTnT浓度加倍,其阳性预测值为100%,阴性预测值为88%。

著录项

  • 来源
    《Clinical Chemistry》 |2010年第4期|p.642-650|共9页
  • 作者单位

    Evangelos Giannitsis,1* Meike Becker,1 Kerstin Kurz,1 Georg Hess,2 Dietmar Zdunek,1 and Hugo A. Katus11 Medizinische Klinik, Abteilung für Innere Medizin III, Universitätsklinikum Heidelberg, Heidelberg, Germany, 2 Roche Diagnostics, Nonnenwald 2, Penzberg, Germany.* Address correspondence to this author at: Medizinische Klinik III, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany. Fax +49-6221-56-5516, e-mail evangelos_giannitsis@med.uni-heidelberg.de.Received July 22, 2009, accepted January 19, 2010.Previously published online at DOI: 10.1373/clinchem.2009.134460Author Contributions: All authors confirmed they have contributed to the intellectual content of this paper and have met the following 3 requirements: (a) significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data, (b) drafting or revising the article for intellectual content, and (c) final approval of the published article.Authors' Disclosures of Potential Conflicts of Interest: Upon manuscript submission, all authors completed the Disclosures of Potential Conflict of Interest form. Potential conflicts of interest:Employment or Leadership: G. Hess, Roche Diagnostics, D. Zdunek, Roche Diagnostics.Consultant or Advisory Role: G. Hess, Roche Diagnostics, E. Giannitsis, Roche Diagnostics.Stock Ownership: None declared.Honoraria: E. Giannitsis, Roche Diagnostics and Mitsubishi Chemicals, H.A. Katus, Roche Diagnostics.Research Funding: E. Giannitsis, Roche Diagnostics. H.A. Katus, Roche Diagnostics, AstraZeneca, Bayer Vital, and Lilly Germany. The investigations were supported by Roche Diagnostics, Germany, which provided hs-cTnT assays.Expert Testimony: None declared.Other: H.A. Katus developed the cTnT assay and holds a patent jointly with Roche Diagnostics.Role of Sponsor: The funding organizations played no role in the design of study, choice of enrolled patients, review and interpretation of data, or preparation or approval of manuscript.,;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号